Skip to content
EntityQ3950557· pop 11· linked from 233 articles

sargramostim

Sign in to save

Also known as B1 61.012, recombinant GM-CSF, Leukine

Sargramostim, sold under the brand name Leukine among others, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that functions as an immunostimulator. It is administered via intravenous infusion or via subcutaneous injection.

Key facts

Drug.O
196
Drug.S
8
Drug.tradename
Leukine, others
Drug.MedlinePlus
a693005
Drug.DailyMedID
Sargramostim
Drug.routes_of_administration
Intravenous, subcutaneous
Drug.ATC_prefix
L03
Drug.ATC_suffix
AA09
Drug.legal_US
Rx-only
Drug.CAS_number
123774-72-1
Drug.DrugBank
DB00020
Drug.ChemSpiderID
none
Drug.UNII
5TAA004E22
Drug.KEGG
D05803
Drug.ChEMBL
1201670
Drug.IUPAC_name
Human granulocyte macrophage colony stimulating factor
Drug.C
639
Drug.H
1006

via Wikipedia infobox

Chemical data

Drug data · ChEMBL

Max clinical phase
Approved
Molecule type
Protein
First approval
1991
Admin. routes
parenteral
Indications
Crohn's disease, prostate carcinoma, Congenital pulmonary alveolar proteinosis, leukemia

via ChEMBL · EBI

~5 min read

Encyclopedic overview

9 sections
Contents
  • Medical uses
  • Contraindications
  • Adverse effects
  • Pharmacology
  • Chemistry
  • History
  • Society and culture
  • Legal status
  • References

Sargramostim, sold under the brand name Leukine among others, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that functions as an immunostimulator. It is administered via intravenous infusion or via subcutaneous injection.

==Medical uses== Sargramostim is primarily used for myeloid reconstitution after autologous or allogeneic bone marrow transplantation. It is also used to treat neutropenia induced by chemotherapy during the treatment of acute myeloid leukemia. Additionally, it is used as a medical countermeasure for treating people who have been exposed to sufficient radiation to suppress bone marrow myelogenesis.

Excerpted from Wikipedia’s “sargramostim” article, available under the CC BY-SA 4.0 licence.